Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Thinq Pharma cro Ltd

    THINQ Pharma is an integrated pharmaceutical company with broad global presence and world class products and services. The company is head quartered in Singapore and has a fully

  • No Image
    Titan Laboratories Pvt Ltd

    Incorporated in 2004, Titan Laboratories Private Limited (TLPL) is engaged in producing sustained & modified release pellets, DC granules and taste masked granules at its WHO-GM

  • No Image
    Toheal Pharma Ltd

    Toheal Pharmachem Limited was established in 1995, with a vision towards Empowering Life and well being, and has rapidly emerged as the premier integrated pharmaceutical company